Brittany M Gibau

Brittany Gibau serves as a key procurement professional within the National Cancer Institute, supporting the agency’s mission to accelerate cancer research through strategic acquisition of scientific and technical services. She manages a portfolio of contracts focused on high-demand research support functions, ensuring alignment with NCI’s priorities in genomic analysis, precision medicine, and translational innovation. Her work centers on securing expert consulting services that enable cutting-edge laboratory operations, data interpretation, and research infrastructure development, often bridging academic and industry capabilities to advance clinical outcomes. Gibau maintains a strong working relationship with Roche Diagnostics Corporation, a leading provider of diagnostic and molecular analysis solutions, reflecting a consistent reliance on industry leaders with deep expertise in oncology-specific technologies. Her procurement approach emphasizes collaboration with vendors capable of delivering scalable, compliant, and scientifically rigorous support services, particularly those with proven capabilities in bioinformatics, clinical trial analytics, and laboratory automation. These partnerships are cultivated to ensure continuity, technical excellence, and rapid deployment of mission-critical resources. Her contracting patterns reveal a pronounced preference for small business set-asides under FAR 19.5, with 60% of her acquisitions reserved for small businesses, demonstrating a robust commitment to socioeconomic diversity in the research ecosystem. This focus ensures that innovative small firms—particularly those with niche expertise in scientific consulting—have meaningful access to federal research funding streams, fostering competition and agility in service delivery. The entirety of Gibau’s procurement activity is concentrated under NAICS 541690, Other Scientific and Technical Consulting Services, underscoring her specialization in procuring advisory, analytical, and operational support services rather than hardware or commodities. Her domain expertise lies in securing consultants who provide bioanalytical strategy, data management, regulatory compliance support, and research optimization—critical enablers for NCI’s high-throughput, precision oncology initiatives.